Project ALS

Project ALS Announces 5th Annual Don't Talk-a-Thon Fundraising Campaign

Retrieved on: 
Wednesday, May 1, 2019
Neurological disorders, Amyotrophic lateral sclerosis, Nervous system, Neurodegenerative disorders, Project ALS, Jenifer Estess, Les Turner ALS Foundation, ALS Association

NEW YORK, May 1, 2019 /PRNewswire/ --Project ALS signals the start of its 5th annual Don't Talk-a-Thon, a digital fundraising campaign in which supporters vow to take at least an hour of silence to raise awareness and funds for amyotrophic lateral sclerosis (ALS) research.

Key Points: 
  • NEW YORK, May 1, 2019 /PRNewswire/ --Project ALS signals the start of its 5th annual Don't Talk-a-Thon, a digital fundraising campaign in which supporters vow to take at least an hour of silence to raise awareness and funds for amyotrophic lateral sclerosis (ALS) research.
  • This year, funds will go towards the Project ALS Therapeutics Core at Columbia, a 3-year, $6.3 million initiative toward the first meaningful therapies for ALS.
  • Jenifer Estess, her sisters and friends, started Project ALS in 1998, when Jenifer was diagnosed with ALS.
  • Project ALS shifted the paradigm of ALS research, requiring its funded researchers and doctors to work together in small teams, toward a new standard of results-oriented accountability.

Project ALS and Columbia University Announce New Screening Platform for ALS Therapeutics

Retrieved on: 
Thursday, April 18, 2019
Neurological disorders, Amyotrophic lateral sclerosis, Nervous system, Neurodegenerative disorders, Project ALS, Jenifer Estess

NEW YORK, April 18, 2019 /PRNewswire/ --Columbia University and Project ALS today announced the Project ALS Therapeutics Core at Columbia, a 3-year, $6.3M initiative toward the first meaningful therapies for ALS.

Key Points: 
  • NEW YORK, April 18, 2019 /PRNewswire/ --Columbia University and Project ALS today announced the Project ALS Therapeutics Core at Columbia, a 3-year, $6.3M initiative toward the first meaningful therapies for ALS.
  • "For twenty years, Project ALS researchers have built tools that allow us to screen potential drugs more efficiently.
  • The Project ALS Therapeutics Core at Columbia aims to bring the first meaningful treatments for ALS from the lab bench to patients, rationally and efficiently.
  • Jenifer Estess, her sisters and friends, started Project ALS in 1998, when Jenifer was diagnosed with ALS.

Global Amyotrophic Lateral Sclerosis Market, 2017-2027: Launch of Five Pipeline Agents that Aim to Extend Patient Survival Driving Market Growth

Retrieved on: 
Friday, January 25, 2019
Nervous system, Rare diseases, Motor neuron diseases, Neurology, Neuroscience, Amyotrophic lateral sclerosis, RTT, Lower motor neuron, Project ALS, Progressive muscular atrophy

This growth will be driven by the launch of six late-stage pipeline products.

Key Points: 
  • This growth will be driven by the launch of six late-stage pipeline products.
  • Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN).
  • The major drivers of growth in the Amyotrophic Lateral Sclerosis (ALS) market during the forecast period include:
    The launch of five pipeline agents that aim to extend patient survival.
  • 2.3 Several Key Unmet Needs Identified in the ALS Market, Providing Opportunity for New Players
    2.5 What Do Physicians Think?